Literature DB >> 14744855

Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1.

Kotaro Hama1, Junken Aoki, Masahiro Fukaya, Yasuhiro Kishi, Teruyuki Sakai, Rika Suzuki, Hideo Ohta, Takao Yamori, Masahiko Watanabe, Jerold Chun, Hiroyuki Arai.   

Abstract

Autotaxin (ATX) is a tumor cell motility-stimulating factor originally isolated from melanoma cell supernatant that has been implicated in regulation of invasive and metastatic properties of cancer cells. Recently, we showed that ATX is identical to lysophospholipase D, which converts lysophosphatidylcholine to a potent bioactive phospholipid mediator, lysophosphatidic acid (LPA), raising the possibility that autocrine or paracrine production of LPA by ATX contributes to tumor cell motility. Here we demonstrate that LPA and ATX mediate cell motility-stimulating activity through the LPA receptor, LPA(1). In fibroblasts isolated from lpa(1)(-/-) mice, but not from wild-type or lpa(2)(-/-), cell motility stimulated with LPA and ATX was completely absent. In the lpa(1)(-/-) cells, LPA-stimulated lamellipodia formation was markedly diminished with a concomitant decrease in Rac1 activation. LPA stimulated the motility of multiple human cancer cell lines expressing LPA(1), and the motility was attenuated by an LPA(1)-selective antagonist, Ki16425. The present study suggests that ATX and LPA(1) represent potential targets for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14744855     DOI: 10.1074/jbc.M313927200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  95 in total

1.  Stimulatory actions of lysophosphatidic acid on mouse ATDC5 chondroprogenitor cells.

Authors:  Ryota Itoh; Shigenori Miura; Aki Takimoto; Shunya Kondo; Hiroko Sano; Yuji Hiraki
Journal:  J Bone Miner Metab       Date:  2010-05-11       Impact factor: 2.626

Review 2.  Insights into the pharmacological relevance of lysophospholipid receptors.

Authors:  Tetsuji Mutoh; Richard Rivera; Jerold Chun
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 3.  International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Timothy Hla; Kevin R Lynch; Sarah Spiegel; Wouter H Moolenaar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 4.  Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance.

Authors:  Mu-En Lin; Deron R Herr; Jerold Chun
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-03-04       Impact factor: 3.072

5.  Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues.

Authors:  Hongjuan Zhao; Cristiane F Ramos; James D Brooks; Donna M Peehl
Journal:  J Cell Physiol       Date:  2007-01       Impact factor: 6.384

Review 6.  CB2 receptor-mediated migration of immune cells: it can go either way.

Authors:  A M Miller; N Stella
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

7.  Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model.

Authors:  Xiaoyu Xu; Glenn D Prestwich
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

8.  Development and biological evaluation of fluorophosphonate-modified hydroxyapatite for orthopaedic applications.

Authors:  Gráinne Neary; Ashley W Blom; Anna I Shiel; Gabrielle Wheway; Jason P Mansell
Journal:  J Mater Sci Mater Med       Date:  2018-07-21       Impact factor: 3.896

Review 9.  Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer.

Authors:  Glenn D Prestwich; Joanna Gajewiak; Honglu Zhang; Xiaoyu Xu; Guanghui Yang; Monica Serban
Journal:  Biochim Biophys Acta       Date:  2008-04-08

10.  Synthesis, pharmacology, and cell biology of sn-2-aminooxy analogues of lysophosphatidic acid.

Authors:  Joanna Gajewiak; Ryoko Tsukahara; Yuko Fujiwara; Gabor Tigyi; Glenn D Prestwich
Journal:  Org Lett       Date:  2008-02-20       Impact factor: 6.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.